Follow the latest coverage, related explainers and connected technology stories.
A U.S. court issued a final judgment requiring Guardant Health to pay more than $245.2 million to TwinStrand Biosciences and the University of Washington after finding it had willfully infringed two patents covering DNA sequencing technologies. The judgment also includes 6% royalties on sales of 11 products and a service until the patents expire in March 2033, while the company plans to appeal the decision.